RMethyMD: an integrated platform for exploring RNA methylation in pan-cancer via a multiomics analysis

Linjie Zhao; Yujie Ren; Chengjun Gong; Shizheng Xiong; Wenyuan Wang; Wanjie Zheng; Jiaxi Zhang; Jiarui Liu; Zhiheng He; Jiafeng Yu; Tingming Liang; Li Guo

doi:10.1016/j.canlet.2025.217462

RMethyMD: an integrated platform for exploring RNA methylation in pan-cancer via a multiomics analysis

Cancer Lett. 2025 Jan 12:217462. doi: 10.1016/j.canlet.2025.217462. Online ahead of print.

Authors

Linjie Zhao¹, Yujie Ren¹, Chengjun Gong¹, Shizheng Xiong¹, Wenyuan Wang¹, Wanjie Zheng¹, Jiaxi Zhang², Jiarui Liu¹, Zhiheng He¹, Jiafeng Yu³, Tingming Liang⁴, Li Guo⁵

Affiliations

¹ State Key Laboratory for Organic Electronics and Information Displays, Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing 210023, China.
² Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University, Nanjing 210023, China.
³ Shandong Provincial Key Laboratory of Biophysics, Institute of Biophysics, Dezhou University, Dezhou, 253023, China.
⁴ Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University, Nanjing 210023, China. Electronic address: tmliang@njnu.edu.cn.
⁵ State Key Laboratory for Organic Electronics and Information Displays, Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing 210023, China. Electronic address: lguo@njupt.edu.cn.

PMID: 39809358
DOI: 10.1016/j.canlet.2025.217462

Abstract

A user-friendly integrated database, RMethyMD (http://www.tmliang.cn/rnamethy), was developed to provide a comprehensive analysis of methylation regulators aimed at facilitating the exploration of molecular features in tumorigenesis and clinical implications in cancer diagnosis and treatment via a multiomics approach. Subsequently, molecular landscapes and a robust constructed m6A-based prognostic model using coxBoost+RSF algorithms in lung cancer highlighted m6A as a suitable marker to guide therapeutic strategy. RMethyMD provides a comprehensive resource and multiomics analysis to explore m6A-based prognostic and clinical values, thereby contributing to aiding personalized cancer therapy.

Keywords: Methylation; database; m6A; pan-cancer; prognosis.